GSK 2696275

Drug Profile

GSK 2696275

Alternative Names: GSK2696275; WAS gene therapy - GlaxoSmithKline/Fondazione Telethon/Ospedale San Raffaele; WAS transduced autologous CD34+ stem cells - GlaxoSmithKline/Fondazione Telethon/Ospedale San Raffaele

Latest Information Update: 10 Dec 2015

Price : $50

At a glance

  • Originator Fondazione Telethon; GlaxoSmithKline; Ospedale San Raffaele
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Gene expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Wiskott-Aldrich syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase II Wiskott-Aldrich syndrome

Most Recent Events

  • 05 Dec 2015 Interim adverse events data from a phase I/II trial in Wiskott-Aldrich Syndrome reported by San Raffaele Telethon Institute for Gene Therapy
  • 29 Jul 2015 Phase-II clinical trials in Wiskott-Aldrich syndrome (In adolescents, In children, In infants, In adults) in Italy (IV)
  • 01 Mar 2015 GlaxoSmithKline, Fondazione Telethon and Ospedale San Raffaele complete enrolment in phase I/II trial for Wiskott Aldrich syndrome (In infants, In children, In adolescents, In adults) in Italy (NCT01515462)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top